diaDexus investigates uterine cancer serum test:
This article was originally published in Clinica
Executive Summary
diaDexus is investigating the feasibility of a noninvasive serum test for uterine and endometrial cancers. The test identifies the gene hESFI (human endometrial specific steroid binding factor I), which is highly expressed in the cancers, or the gene's protein. The Santa Clara, California firm recently received a US patent covering the technology.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.